Blueprint
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 16 April 2019
 
GlaxoSmithKline plc
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
 
 
 
GlaxoSmithKline plc (the 'Company')
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
 
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.6560
908.000
£15.6560
260.000
£15.6560
912.000
£15.6560
260.000
d)
Aggregated information
 
Aggregated volume 
Price
 
 
 
2340.000 
£15.6560
 
e)
Date of the transaction
2019-04-12 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
  Name
Dr H Barron
b)
  Position/status
Chief Scientific Officer and President, R&D
 
c)
  Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 
b)
Nature of the transaction
Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$ 40.9400
538.000
d)
Aggregated information
Aggregated volume 
Price
 
n/a (single transaction)
 
 
 
 
e)
Date of the transaction
2019-04-12
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
  
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Vaccines
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.6560
238.000
£15.6560
135.000
£15.6560
193.000
£15.6560
135.000
d)
Aggregated information
 
Aggregated volume
Price
 
 
 
701.000 
£15.6560
  
e)
Date of the transaction
2019-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
  
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S P Dingemans
b)
Position/status
Executive Director
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
b)
Nature of the transaction
Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.6560
649.000
£15.6560
236.000
£15.6560
645.000
£15.6560
236.000
d)
Aggregated information
 
Aggregated volume
Price
 
 
 
1766.000 
£15.6560
 
e)
Date of the transaction
2019-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position/status
SVP and General Counsel
 
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 
b)
Nature of the transaction
Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$ 40.9400
46.000
d)
Aggregated information
 
Aggregated volume
Price
n/a (single transaction)
 
e)
Date of the transaction
2019-04-12
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.6560
99.000
£15.6560
85.000
£15.6560
101.000
£15.6560
85.000
d)
Aggregated information
 
Aggregated volume
Price
 
 
 
370.000 
£15.6560
 
e)
Date of the transaction
2019-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
  
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
 
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 
b)
Nature of the transaction
Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$ 40.9400
90.000
$ 40.9400
98.000
$ 40.9400
96.000
d)
Aggregated information
 
Aggregated volume
Price
 
 
 
284.000 
$ 40.9400
e)
Date of the transaction
2019-04-12
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
  
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Miels
b)
Position/status
President, Global Pharmaceuticals
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.6560
253.000
£15.6560
183.000
d)
Aggregated information
 
Aggregated volume
Price
 
 
 
436.000£15.6560
 
e)
Date of the transaction
2019-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
  
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.6560
225.000
£15.6560
107.000
£15.6560
187.000
£15.6560
107.000
d)
Aggregated information
 
Aggregated volume
Price
 
 
 
626.000 
£15.6560
 
e)
Date of the transaction
2019-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
  
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Simard
b)
Position/status
President, Pharmaceuticals Supply Chain
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.6560
81.000
d)
Aggregated information
 
Aggregated volume 
Price
 
n/a (single transaction)
 
 
 
e)
Date of the transaction
2019-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
  
  
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms K Terrell
b)
Position/status
Chief Digital & Technology Officer
 
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 
b)
Nature of the transaction
Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$ 40.9400
114.000
$ 40.9400
32.000
d)
Aggregated information
 
Aggregated volume
Price
 
 
 
146.000
$ 40.9400
  
e)
Date of the transaction
2019-04-12
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
President, Global Affairs
 
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.6560
131.000
£15.6560
102.000
£15.6560
126.000
d)
Aggregated information
 
Aggregated volume
Price
 
 
 
359.000 
£15.6560
 
e)
Date of the transaction
2019-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: April 16, 2019 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc